Drugs / RSV MAT vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05169905 | Feb → Aug 2022 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSV MAT vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05169905 ↗ |
| Modality | Vaccine | “RSV MAT vaccine” NCT05169905 ↗ |